When It Comes To These 2 Biopharma Stocks’ Near-Term Gains, Analysts Are Seeing (More Than) Double!

Today’s article highlights two clinical-stage biopharmaceutical stocks that analysts expect to more than double in the coming months — one engaged in discovering and developing customized medicines to treat solid tumors and blood malignancies and the second focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. For more on these two biopharma stocks and their 100%+ upside potential, CLICK HERE.